Celecoxib and radiation therapy in non-small-cell lung cancer. Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):10-4
Date
02/03/2005Pubmed ID
15685827Scopus ID
2-s2.0-17944376453 (requires institutional sign-in at Scopus site) 23 CitationsAbstract
Overexpression of cyclooxygenase-2 (COX-2) is frequently present in lung cancer and may play a significant role in carcinogenesis, invasion, and metastasis. It has been associated with shortened survival in patients with resected early-stage adenocarcinoma of the lung. COX-2 inhibition decreases tumor cell proliferation in vivo and has been shown to enhance tumor radiosensitivity. Additionally, COX-2 inhibition may protect normal pulmonary tissue from radiation fibrosis. Clinical studies are under way to assess the potential benefits and risks of COX-2 inhibition in the treatment of lung cancer. The rationale for COX-2 inhibitors in the treatment of lung cancer will be reviewed. The results of a phase II study assessing the acute toxicity of concurrent celecoxib (Celebrex) and thoracic irradiation in patients with non-small-cell lung cancer (NSCLC) are reported, and an ongoing Radiation Therapy Oncology Group study using celecoxib and concurrent radiation therapy for NSCLC in patients with intermediate prognostic factors is reviewed.
Author List
Gore EAuthor
Elizabeth M. Gore MD Professor in the Radiation Oncology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Carcinoma, Non-Small-Cell LungCelecoxib
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Cyclooxygenase Inhibitors
Humans
Lung Neoplasms
Neoplasm Staging
Prognosis
Pulmonary Fibrosis
Pyrazoles
Radiation Injuries
Radiotherapy Dosage
Radiotherapy, Adjuvant
Sulfonamides
Treatment Outcome
